直接口服抗凝剂在白内障手术期间和之后对出血的影响
Anat Maytal1,2, Hadar Naidorf Rosenblatt3, Reut Rotem4
1Department of Ophthalmology, Meir Medical Center, Meir Hospital, 59 Tchernichovsky St, 4428164, Kfar Saba, Israel. anat.maytal1@gmail.com.
International ophthalmology
|February 20, 2024
概括
在化手术期间继续使用直接口服抗凝剂 (DOAC) 不会增加眼部出血的风险. 这项研究发现,白内障手术对于不间断接受DOAC治疗的患者来说是安全的.
科学领域:
- 眼科医生 眼科 眼科
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 直接口服抗凝剂 (DOAC) 越来越多地被处方用于血栓栓塞状况.
- 发光乳化手术是一种常见的白内障手术,存在手术内和手术后出血的风险.
- 在化过程中继续使用DOAC的安全性是一个临床问题.
研究的目的:
- 为了评估在接受不间断的DOACs的患者在法化手术期间和之后眼部出血的风险.
- 为了比较服用DOACs的患者和不接受抗血栓治疗的对照组之间的出血并发症率.
主要方法:
- 研究了一系列连续接受眼内透镜植入法化治疗的患者,同时接受不间断的DOACs (达比加特兰,里瓦罗克萨班,阿皮克萨班).
- 没有抗血栓治疗的性别和年龄匹配的对照组被用于比较.
- 患者在术后被评估出血和非出血并发症.
主要成果:
- 在DOAC的40名患者 (56只眼睛) 和对照组的120名患者 (172只眼睛) 接受了发酵.
- 两组之间没有观察到手术内或手术后出血率的显著差异.
- 低血发生在1.8%的DOAC组和1.7%的对照组;没有报告的血栓栓塞事件.
结论:
- 在继续接受直接口服抗凝药治疗的患者中,可安全地进行化手术.
- 不间断的DOAC治疗似乎不会增加白内障手术期间眼部出血的风险.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Disorders of Hemostasis
906
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
906
Angle Closure Glaucoma: Treatment
498
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
498
Extrinsic and Intrinsic Pathways of Hemostasis
7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K


